Market Closed -
Nasdaq
04:00:00 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
4.8
USD
|
-4.00%
|
|
+8.23%
|
+12.41%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
598.9
|
355.3
|
216.2
|
246.7
|
-
|
-
|
Enterprise Value (EV)
1 |
333.9
|
89.01
|
216.2
|
246.7
|
246.7
|
246.7
|
P/E ratio
|
-2.06
x
|
-1.31
x
|
-0.97
x
|
-1.62
x
|
-6.01
x
|
-3.62
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
11
x
|
3.88
x
|
2.15
x
|
5.03
x
|
2.39
x
|
3.02
x
|
EV / Revenue
|
11
x
|
3.88
x
|
2.15
x
|
5.03
x
|
2.39
x
|
3.02
x
|
EV / EBITDA
|
-2.01
x
|
-1.41
x
|
-0.95
x
|
-1.5
x
|
-2.85
x
|
-2.52
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
1.68
x
|
1.14
x
|
0.82
x
|
1.72
x
|
1.64
x
|
-
|
Nbr of stocks (in thousands)
|
23,369
|
37,917
|
50,625
|
51,405
|
-
|
-
|
Reference price
2 |
25.63
|
9.370
|
4.270
|
4.800
|
4.800
|
4.800
|
Announcement Date
|
3/22/22
|
3/16/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
54.52
|
91.5
|
100.4
|
49.05
|
103.4
|
81.82
|
EBITDA
1 |
-
|
-297.6
|
-251.6
|
-227.3
|
-164.4
|
-86.66
|
-98.06
|
EBIT
1 |
-
|
-313.9
|
-263.1
|
-237.6
|
-158.2
|
-80.34
|
-90.92
|
Operating Margin
|
-
|
-575.82%
|
-287.6%
|
-236.69%
|
-322.62%
|
-77.7%
|
-111.12%
|
Earnings before Tax (EBT)
1 |
-
|
-292.2
|
-254.2
|
-217.6
|
-161.4
|
-79.17
|
-114.9
|
Net income
1 |
-120.1
|
-292.2
|
-254.2
|
-217.6
|
-162.2
|
-47.28
|
-98.98
|
Net margin
|
-
|
-535.95%
|
-277.77%
|
-216.73%
|
-330.59%
|
-45.72%
|
-120.96%
|
EPS
2 |
-5.000
|
-12.44
|
-7.130
|
-4.420
|
-2.966
|
-0.7983
|
-1.325
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/8/21
|
3/22/22
|
3/16/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
16.03
|
8.429
|
13.48
|
13.41
|
56.18
|
41.62
|
36.05
|
12.03
|
10.68
|
12.44
|
11.82
|
11.11
|
12.32
|
12.6
|
13.2
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-45.75
|
-
|
-56.91
|
-49.05
|
-43.87
|
-38.38
|
-36.47
|
-
|
-
|
EBIT
1 |
-68.37
|
-90.59
|
-76.97
|
-68.37
|
-27.21
|
-51.71
|
-47.99
|
-57.3
|
-59.94
|
-51.15
|
-40.31
|
-35.4
|
-31.37
|
-
|
-
|
Operating Margin
|
-426.44%
|
-1,074.72%
|
-570.92%
|
-509.9%
|
-48.44%
|
-124.25%
|
-133.13%
|
-476.13%
|
-560.99%
|
-411.37%
|
-340.94%
|
-318.78%
|
-254.54%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-60.97
|
-85.71
|
-77.4
|
-67.88
|
-23.14
|
-47.02
|
-42.09
|
-71.64
|
-56.82
|
-52.67
|
-38.51
|
-37.06
|
-33.94
|
-
|
-
|
Net income
1 |
-60.97
|
-85.71
|
-77.42
|
-67.88
|
-23.14
|
-47.02
|
-42.09
|
-71.64
|
-56.82
|
-52.67
|
-38.51
|
-37.06
|
-33.94
|
-
|
-
|
Net margin
|
-380.3%
|
-1,016.86%
|
-574.25%
|
-506.26%
|
-41.2%
|
-112.97%
|
-116.76%
|
-595.3%
|
-531.84%
|
-423.59%
|
-325.65%
|
-333.72%
|
-275.43%
|
-
|
-
|
EPS
2 |
-2.550
|
-3.200
|
-2.020
|
-1.760
|
-0.6000
|
-1.080
|
-0.8300
|
-1.400
|
-1.110
|
-1.010
|
-0.7420
|
-0.6540
|
-0.5600
|
-0.2400
|
-0.2300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/22/22
|
5/12/22
|
8/10/22
|
11/7/22
|
3/16/23
|
5/3/23
|
8/14/23
|
11/14/23
|
3/5/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
265
|
266
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-135%
|
-75.8%
|
-76.9%
|
-65%
|
-23%
|
-4.49%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
15.30
|
8.190
|
5.180
|
2.790
|
2.920
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
11.6
|
22.8
|
13.9
|
12.4
|
13
|
-
|
Capex / Sales
|
-
|
21.23%
|
24.97%
|
13.81%
|
25.32%
|
12.61%
|
-
|
Announcement Date
|
10/8/21
|
3/22/22
|
3/16/23
|
3/5/24
|
-
|
-
|
-
|
Average target price
10.5
USD Spread / Average Target +118.75% Consensus |
1st Jan change
|
Capi.
|
---|
| +12.41% | 257M | | +33.63% | 50.85B | | -0.09% | 42.82B | | +49.62% | 42.03B | | -4.96% | 29.55B | | +11.18% | 26.11B | | -21.95% | 19.13B | | +8.61% | 13.05B | | +28.31% | 12.16B | | +24.73% | 12.08B |
Other Biotechnology & Medical Research
|